FDA Advisory Panel Supports Staar Surgical Visian Toric Lens
This article was originally published in The Gray Sheet
FDA’s Ophthalmic Devices Panel voted in favor of Staar Surgical’s Visian toric implantable collamer lens to correct myopic astigmatism in adults ages 21 to 45. Earlier safety and missing data questions on the lenses were reviewed, but ultimately, the panel said the product’s proposed indication outweighed risk for use in specified patients.
You may also be interested in...
FDA is asking its Ophthalmic Devices Panel to consider the implications of missing data and issues with sizing methodology issues tied to Staar Surgical’s PMA submission for its Visian toric implantable collamer lens to correct myopic astigmatism in adults ages 21 to 45. The panel was scheduled for Feb. 14, but it has been postponed due to weather.
Informa Pharma Intelligence has officially launched the seventh Global Generics & Biosimilars Awards, which will take place in October 2020 in Milan, Italy.
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.